Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Oct 20;7(10):319.
doi: 10.3390/tropicalmed7100319.

Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis

Affiliations
Case Reports

Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis

Tommaso Lupia et al. Trop Med Infect Dis. .

Abstract

The reactivation of latent Leishmania infection in chronic diseases and immunocompromised hosts is a broad and heterogeneous field in medicine and infectious diseases. We reported one of the first cases of Visceral Leishmaniasis occurring in a Caucasian middle-aged man living in an endemic country (Italy) for Leishmania infantum infection following secukinumab treatment for psoriatic arthritis. The patient was cured with a Liposomal Amphotericin B (L-AmB, 3 mg/Kg on days 1-5, followed by a dose on days 10, 17, 24, 31 and 38) regimen, after which his anti-interleukin 17 treatment was restarted-without recurrence in the follow-up.

Keywords: Leishmania; arthritis; interleukin-17; psoriasis; secukinumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Timeline of treatment of psoriasis until diagnostic of visceral leishmaniasis. Abbreviations: MTX: metothrexate.
Figure 2
Figure 2
Hematoxylin-eosine stain on osteomedullary biopsy showing amastigotes (black arrows). Caption: Hematoxylin-eosin shows histiocytes containing innumerable hematoxylinophilic corpuscles compatible with Leishmania amastigotes (arrows), also present in the interstitium (20×).

References

    1. Blauvelt A., Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin. Rev. Allergy Immunol. 2018;55:379–390. doi: 10.1007/s12016-018-8702-3. - DOI - PMC - PubMed
    1. Keijsers R.R.M.C., Joosten I., van Erp P.E.J., Koenen H.J.P.M., van de Kerkhof P.C.M. Cellular sources of IL-17 in psoriasis: A paradigm shift? Exp. Dermatol. 2014;23:799–803. doi: 10.1111/exd.12487. - DOI - PubMed
    1. Lande R., Botti E., Jandus C., Dojcinovic D., Fanelli G., Conrad C., Chamilos G., Feldmeyer L., Marinari B., Chon S., et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat. Commun. 2014;5:5621. doi: 10.1038/ncomms6621. - DOI - PubMed
    1. Pitta M.G., Romano A., Cabantous S., Henri S., Hammad A., Kouriba B., Argiro L., El Kheir M., Bucheton B., Mary C., et al. IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani. J. Clin. Investig. 2009;119:2379–2387. doi: 10.1172/JCI38813. - DOI - PMC - PubMed
    1. Banerjee A., Bhattacharya P., Joshi A.B., Ismail N., Dey R., Nakhasi H.L. Role of pro-inflammatory cytokine IL-17 in Leishmania pathogenesis and in protective immunity by Leishmania vaccines. Cell Immunol. 2016;309:37–41. doi: 10.1016/j.cellimm.2016.07.004. - DOI - PubMed

Publication types

LinkOut - more resources